Details

Autor(en) / Beteiligte

• Huo, T.-I
• Lin, H.-C
• Hsia, C.-Y
• Huang, Y.-H
• Wu, J.-C
• Chiang, J.-H
• Chiou, Y.-Y
• Lui, W.-Y
• Lee, P.-C
• Lee, S.-D

Titel

The MELD-Na is an independent short- and long-term prognostic predictor for hepatocellular carcinoma: A prospective survey

Ist Teil von

• Digestive and liver disease, 2008-11, Vol.40 (11), p.882-889

Ort / Verlag

Netherlands: Elsevier Ltd

Erscheinungsjahr

2008

Quelle

Elsevier ScienceDirect Journals

Beschreibungen/Notizen

• Abstract Background and aim Serum sodium has been suggested to incorporate into the model for end-stage liver disease to enhance its prognostic ability for cirrhosis. A mathematical equation based on model for end-stage liver disease and sodium, known as “MELD-Na”, was developed for outcome prediction for cirrhosis. The severity of liver cirrhosis is a key component to predict survival in patients with hepatocellular carcinoma. This study investigated the prognostic role of MELD-Na for hepatocellular carcinoma. Patients and methods A total of 535 unselected hepatocellular carcinoma patients were prospectively enrolled to evaluate the performance of MELD-Na. Results The MELD-Na was better than model for end-stage liver disease in predicting 6-month mortality by comparing the area under receiver operating characteristic curve (0.782 vs. 0.761, p = 0.101). MELD-Na, but not model for end-stage liver disease, was an independent predictor associated with 6-month mortality in multivariate logistic regression analysis (odds ratio: 1.14, p = 0.001). In the survival analysis, MELD-Na also independently predicted mortality, with an additional risk of 4.3% per unit increment of the score ( p < 0.001). Patients with MELD-Na scores between 10 and 20 and scores >20 had 2.1-fold ( p < 0.001) and 7.5-fold ( p < 0.001) risk of mortality, respectively, compared to patients with a score <10 in the Cox proportional hazard model. Conclusion The MELD-Na score is a feasible and independent prognostic predictor for both short- and long-term outcome predictions in patients with hepatocellular carcinoma.